Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective Prevalence Study in Adolescent and Adult Patients Dependent on Parenteral Nutrition to Assess the Incidence of Intestinal Failure-Associated Liver Disease

X
Trial Profile

A Prospective Prevalence Study in Adolescent and Adult Patients Dependent on Parenteral Nutrition to Assess the Incidence of Intestinal Failure-Associated Liver Disease

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Sep 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Choline chloride (Primary)
  • Indications Liver disorders
  • Focus Therapeutic Use
  • Acronyms THRIVE-1
  • Sponsors Protara Therapeutics
  • Most Recent Events

    • 09 Sep 2024 According to a Protara Therapeutics media release, data from this trial presented at the 46th European Society for Clinical Nutrition and Metabolism Congress (ESPEN).
    • 09 Sep 2024 Results published in the Protara Therapeutics Media Release
    • 29 Sep 2023 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top